hyperammonemic crises

临床试验

计划入组 10 人 · 首次发布于 2023 年 3 月 3 日

已完成

NCT01624311

Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young Infants

计划入组 5 人 · 首次发布于 2012 年 6 月 20 日

招募中

NCT05471232

Mental Health Crises in Youth With IDDs

计划入组 150 人 · 首次发布于 2022 年 7 月 22 日

药物

查看全部 143 →

Biotech

Approved

Crizanlizumab(Adakveo)

Methyldopa

相关疾病：Hypertension, Hypertensive crisis

C₁₀H₁₃NO₄ · Rx

Small Molecule

Approved

Voxelotor(Oxbryta)

相关疾病：Hemolytic Anemia, Sickle Cell Disease (SCD)

C₁₉H₁₉N₃O₃ · Rx

机构

查看全部 54 →

Irisys, Inc.

United States

CRISPR Therapeutics

United States

CRISPR Therapeutics, Inc.

United States

资讯

查看全部 1496 →

去年

Ravicti Receives Regulatory Approval in Saudi Arabia, Qatar, and Kuwait for Urea Cycle Disorders

10个月前

Korro Bio's RNA Editing Drug Shows Promise but Falls Short of Efficacy Targets in Alpha-1 Antitrypsin Deficiency Trial

6个月前

临床试验

Optimalisation of the Treatment of Acute Neonatal Hyperammonaemia

Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young Infants

Mental Health Crises in Youth With IDDs

药物

Crizanlizumab(Adakveo)

Methyldopa

Voxelotor(Oxbryta)

机构

Irisys, Inc.

CRISPR Therapeutics

CRISPR Therapeutics, Inc.

资讯

Ravicti Receives Regulatory Approval in Saudi Arabia, Qatar, and Kuwait for Urea Cycle Disorders

Korro Bio's RNA Editing Drug Shows Promise but Falls Short of Efficacy Targets in Alpha-1 Antitrypsin Deficiency Trial

Korro Bio Advances RNA Editing Platform with KRRO-121 Nomination and $85 Million Financing